FOLH1 and neoplasm: Several tumor‐specific or associated antigens, including prostate‐specific antigen (PSA), prostate‐specific membrane antigen (PSMA), and prostate acid phosphatase (PAP), have demonstrated significant therapeutic potential in treating PCa.